Last reviewed · How we verify
Placebo (for dronedarone)
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Control arm in clinical trials for dronedarone (atrial fibrillation management).
At a glance
| Generic name | Placebo (for dronedarone) |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Placebo serves as a comparator arm in randomized controlled trials to establish the efficacy of the active drug (dronedarone) by isolating its true therapeutic effect from placebo response. Any observed benefits in the placebo group reflect natural disease progression, regression to the mean, and psychological/expectation effects rather than pharmacological action.
Approved indications
- Control arm in clinical trials for dronedarone (atrial fibrillation management)
Common side effects
Key clinical trials
- Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence (PHASE4)
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (PHASE3)
- Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation (PHASE4)
- Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (PHASE2)
- Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA) (PHASE4)
- Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation (PHASE2)
- Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers (PHASE4)
- Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for dronedarone) CI brief — competitive landscape report
- Placebo (for dronedarone) updates RSS · CI watch RSS
- Sanofi portfolio CI